Genovis

Genovis EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genovis (GENO.ST) as of Oct 18, 2026 is 27.49 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 56.18 M SEK — a change of -51.06% (lower).

EBITDA

27.49 MSEK

YoY

-51.06%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genovis is 2025 27.49 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genovis was 2024 56.18 M SEK. It decreases by -51.06% lower compared to the previous year.

The Genovis EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
2.08 M SEK
Jan 1, 2019
17.02 M SEK
Jan 1, 2020
12.32 M SEK
Jan 1, 2021
30.31 M SEK
Jan 1, 2022
15.19 M SEK
Jan 1, 2023
63.95 M SEK
Jan 1, 2024
56.18 M SEK
Jan 1, 2025
27.49 M SEK
The Genovis EBITDA history
YEAREBITDAYoY
27.49 MSEK-51.06%
56.18 MSEK-12.15%
63.95 MSEK+320.98%
15.19 MSEK-49.89%
30.31 MSEK+146.06%
12.32 MSEK-27.62%
17.02 MSEK+718.92%
2.08 MSEK-133.38%
-6.23 MSEK-53.80%
-13.48 MSEK-27.18%
-18.51 MSEK-3.62%
-19.20 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genovis stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genovis is 27.49 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genovis changed from 56.18 M SEK to 27.49 M SEK, representing a -51.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Genovis since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Genovis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genovis

All Key Metrics — Genovis